Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 4 |
Neoplasms | 3 |
Nervous System Diseases | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Unknown | 1 |
Inactivated vaccine | 1 |
Prophylactic vaccine | 1 |
Diagnostic radiopharmaceuticals | 1 |
Target |
Mechanism ATP7A modulators [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDHK inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2026 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date31 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Copper Histidine ( ATP7A ) | Menkes Kinky Hair Syndrome More | Phase 3 |
Sodium Dichloroacetate ( PDHK ) | Pyruvate Dehydrogenase Complex Deficiency Disease More | Phase 3 |
Acyline ( GnRHR ) | Contraception More | Phase 2 Clinical |
TMTDS | Turner Syndrome More | Phase 2 |
[18F]-6F-DA | Endocrine System Diseases More | Phase 1 |